Your request to link to rcsb for Cytochrome P450 3A

---

• 1TQN: crystal structure of human microsomal p450 3a4 (10.1074/JBC.C400293200 )
• 1W0E: crystal structure of human cytochrome p450 3a4 (10.1126/SCIENCE.1099736 )
• 1W0F: crystal structure of human cytochrome p450 3a4 (10.1126/SCIENCE.1099736 )
• 1W0G: crystal structure of human cytochrome p450 3a4 (10.1126/SCIENCE.1099736 )
• 2J0D: crystal structure of human p450 3a4 in complex with erythromycin (10.1073/PNAS.0603236103 )
• 2V0M: crystal structure of human p450 3a4 in complex with ketoconazole (10.1073/PNAS.0603236103 )
• 3NXU: crystal structure of human cytochrome p4503a4 bound to an inhibitor ritonavir (10.1073/PNAS.1010693107 )
• 3TJS: crystal structure of the complex between human cytochrome p450 3a4 and desthiazolylmethyloxycarbonyl ritonavir (10.1016/J.ABB.2012.02.018 )
• 3UA1: crystal structure of the cytochrome p4503a4-bromoergocryptine complex (10.1074/JBC.M111.317081 )
• 4D6Z: cytochrome p450 3a4 bound to imidazole and an inhibitor (10.1021/ACS.JMEDCHEM.5B01146 )
• 4D75: cytochrome p450 3a4 bound to an inhibitor (10.1021/ACS.JMEDCHEM.5B01146 )
• 4D78: cytochrome p450 3a4 bound to an inhibitor (10.1021/ACS.JMEDCHEM.5B01146 )
• 4D7D: cytochrome p450 3a4 bound to an inhibitor (10.1021/ACS.JMEDCHEM.5B01146 )
• 4I3Q: crystal structure of human cyp3a4 coordinated to a water molecule (10.1021/JM400288Z )
• 4I4G: crystal structure of cyp3a4 ligated to oxazole-substituted desoxyritonavir (10.1021/JM400288Z )
• 4I4H: crystal structure of cyp3a4 ligated to pyridine-substituted desoxyritonavir (10.1021/JM400288Z )
• 4K9T: complex of cyp3a4 with a desoxyritonavir analog (10.1021/BI4005396 )
• 4K9U: complex of human cyp3a4 with a desoxyritonavir analog (10.1021/BI4005396 )
• 4K9V: complex of cyp3a4 with a desoxyritonavir analog (10.1021/BI4005396 )
• 4K9W: complex of human cyp3a4 with a desoxyritonavir analog (10.1021/BI4005396 )
• 4K9X: complex of human cyp3a4 with a desoxyritonavir analog (10.1021/BI4005396 )
• 4NY4: crystal structure of cyp3a4 in complex with an inhibitor (10.1016/J.DRUDIS.2014.03.012 )
• 5A1P: crystal structure of cytochrome p450 3a4 bound to progesterone and citrate (10.1021/ACS.BIOCHEM.5B00510 )
• 5A1R: crystal structure of cytochrome p450 3a4 bound to progesterone (10.1021/ACS.BIOCHEM.5B00510 )
• 5G5J: crystal structure of human cyp3a4 bound to metformin (10.1016/J.CHEMBIOL.2017.08.009 )
• 5TE8: crystal structure of the midazolam-bound human cyp3a4 (10.1073/PNAS.1616198114 )
• 5VC0: crystal structure of human cyp3a4 bound to ritonavir (10.1021/ACS.BIOCHEM.7B00334 )
• 5VCC: crystal structure of human cyp3a4 bound to glycerol (10.1021/ACS.BIOCHEM.7B00334 )
• 5VCD: crystal structure of the cysteine depleted cyp3a4 bound to glycerol (10.1021/ACS.BIOCHEM.7B00334 )
• 5VCE: crystal structure of the cysteine depleted cyp3a4 bound to ritonavir (10.1021/ACS.BIOCHEM.7B00334 )
• 5VCG: crystal structure of the cysteine depleted cyp3a4 bound to bromoergocryptine (10.1021/ACS.BIOCHEM.7B00334 )
• 6BCZ: crystal structure of human cyp3a4 bound to an inhibitor (10.1021/ACS.MOLPHARMACEUT.7B00957 )
• 6BD5: crystal structure of human cyp3a4 bound to an inhibitor (10.1021/ACS.MOLPHARMACEUT.7B00957 )
• 6BD6: crystal structure of human cyp3a4 bound to an inhibitor (10.1021/ACS.MOLPHARMACEUT.7B00957 )
• 6BD7: crystal structure of human cyp3a4 bound to an inhibitor
• 6BD8: crystal structure of human cyp3a4 bound to an inhibitor
• 6BDH: crystal structure of human cyp3a4 bound to an inhibitor
• 6BDI: crystal structure of human cyp3a4 bound to an inhibitor
• 6BDK: crystal structure of human cyp3a4 bound to an inhibitor (10.1021/ACS.MOLPHARMACEUT.7B00957 )
• 6BDM: crystal structure of human cyp3a4 bound to an inhibitor
• 6DA2: human cyp3a4 bound to an inhibitor (10.1021/ACS.BIOCHEM.9B00156 )
• 6DA3: human cyp3a4 bound to an inhibitor (10.1021/ACS.BIOCHEM.9B00156 )
• 6DA5: human cyp3a4 bound to an inhibitor (10.1021/ACS.BIOCHEM.9B00156 )
• 6DA8: human cyp3a4 bound to an inhibitor (10.1021/ACS.BIOCHEM.9B00156 )
• 6DAA: human cyp3a4 bound to an inhibitor (10.1021/ACS.BIOCHEM.9B00156 )
• 6DAB: human cyp3a4 bound to an inhibitor (10.1021/ACS.BIOCHEM.9B00156 )
• 6DAC: human cyp3a4 bound to an inhibitor (10.1021/ACS.BIOCHEM.9B00156 )
• 6DAG: human cyp3a4 bound to an inhibitor (10.1021/ACS.BIOCHEM.9B00156 )
• 6DAJ: human cyp3a4 bound to an inhibitor (10.1021/ACS.BIOCHEM.9B00156 )
• 6DAL: human cyp3a4 bound to an inhibitor (10.1021/ACS.BIOCHEM.9B00156 )
• 6MA6: human cyp3a4 bound to an inhibitor metyrapone (10.1021/ACS.BIOCHEM.8B01221 )
• 6MA7: human cyp3a4 bound to an inhibitor fluconazole (10.1021/ACS.BIOCHEM.8B01221 )
• 6MA8: human cyp3a4 bound to pmsf (10.1021/ACS.BIOCHEM.8B01221 )
• 6OO9: human cyp3a4 bound to a drug mibefradil (10.3390/IJMS20174245 )
• 6OOA: human cyp3a4 bound to a drug substrate (10.3390/IJMS20174245 )
• 6OOB: human cyp3a4 bound to a suicide substrate (10.3390/IJMS20174245 )
• 6UNE: human cyp3a4 bound to an inhibitor (10.1016/J.BMC.2020.115349 )
• 6UNG: human cyp3a4 bound to an inhibitor (10.1016/J.BMC.2020.115349 )
• 6UNH: human cyp3a4 bound to an inhibitor (10.1016/J.BMC.2020.115349 )
• 6UNI: human cyp3a4 bound to an inhibitor (10.1016/J.BMC.2020.115349 )
• 6UNJ: human cyp3a4 bound to an inhibitor (10.1016/J.BMC.2020.115349 )
• 6UNK: human cyp3a4 bound to an inhibitor (10.1016/J.BMC.2020.115349 )
• 6UNL: cyp3a4 bound to an inhibitor (10.1016/J.BMC.2020.115349 )
• 6UNM: cyp3a4 bound to an inhibitor (10.1016/J.BMC.2020.115349 )
• 7KS8: crystal structure of human cyp3a4 with the caged inhibitor
• 7KSA: crystal structure of human cyp3a4 with the caged inhibitor
• 7KVH: human cyp3a4 bound to an inhibitor (10.3390/IJMS22020852 )
• 7KVI: human cyp3a4 bound to an inhibitor (10.3390/IJMS22020852 )
• 7KVJ: human cyp3a4 bound to an inhibitor (10.3390/IJMS22020852 )
• 7KVK: human cyp3a4 bound to an inhibitor (10.3390/IJMS22020852 )
• 7KVM: human cyp3a4 bound to an inhibitor (10.3390/IJMS22020852 )
• 7KVN: human cyp3a4 bound to an inhibitor (10.3390/IJMS22020852 )
• 7KVO: human cyp3a4 bound to an inhibitor (10.3390/IJMS22020852 )
• 7KVP: human cyp3a4 bound to an inhibitor (10.3390/IJMS22020852 )
• 7KVQ: human cyp3a4 bound to an inhibitor (10.3390/IJMS22020852 )
• 7KVS: human cyp3a4 bound to an inhibitor (10.3390/IJMS22020852 )
• 7LXL: crystal structure of human cyp3a4 bound to the testosterone dimer
• 7MK8: crystal structure of a surface mutant of human fetal-specific cyp3a7 bound to dithiothreitol